• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Monday, August 24, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Genetic variation may increase risk of liver damage in patients with chronic hepatitis B

Bioengineer by Bioengineer
July 26, 2018
in Health
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram
IMAGE

Credit: The Westmead Institute for Medical Research

A new study has shown that genetic variation may increase the risk of severe liver damage in Caucasians with chronic hepatitis B infection.

Researchers from the Westmead Institute for Medical Research found that Caucasian patients with a variation in their STAT4 gene were more likely to experience inflammation and severe liver fibrosis.

Dr Rasha El Sharkawy, the first author of the study, said the findings add to the growing body of evidence that demonstrates a link between genes and the progression of hepatitis B.

"The progression of liver injury in hepatitis B can vary significantly among patients, which indicates that genetic factors may play a role," Dr El Sharkawy said.

The STAT4 gene is part of the body's immune response against viruses and regulates tissue inflammation, fibrosis and anti-viral activity.

"We found that patients with the risk genetic variation had lower expression of STAT4 in their liver and immune cells, reducing their immune response against hepatitis B and their production of interferon gamma, a protein responsible for moderating fibrosis.

"This may, at least partially explain why patients with the variation experience poorer liver health," Dr El Sharkawy explained.

Approximately one third of the world's population have come into contact with hepatitis B, with 350-400 million people developing a chronic infection. If left untreated, chronic infections can lead to liver injury, liver cancer, and liver failure, with more than one million deaths attributed to cirrhosis and cancer each year.

"Not everyone who comes into contact with the virus will develop a chronic infection, but those that do, require treatment to prevent severe complications, including liver failure and damage," Dr El Sharkawy said.

Professor Jacob George and Associate Professor Mohammed Eslam, leaders of the research study, said that with further study, researchers could better understand how the STAT4 gene affects the progression of hepatitis B, so that they can prevent liver injury and failure in at-risk groups.

###

Media Contact

Alison Grinyer
[email protected]
@TheWestmead

http://www.westmeadinstitute.org.au/

Original Source

https://www.westmeadinstitute.org.au/news-and-events/2018/genetic-variation-may-increase-risk-of-liver-damag http://dx.doi.org/10.1111/apt.14866

Share12Tweet8Share2ShareShareShare2

Related Posts

Blocking glucosylceramide production kills cancer cells via lysosomal dysfunction, not ceramide buildup

August 23, 2026

ZCCHC4 boosts replication-dependent histone mRNA translation by interacting with eIF3

August 23, 2026

Tirzepatide Versus GLP-1 Agonists for Stroke Risk in Atrial Fibrillation and Diabetes

August 22, 2026

Real-world study examines psychotic complications of subcutaneous foslevodopa/foscarbidopa infusions in 198 patients

August 22, 2026
Please login to join discussion

POPULAR NEWS

  • KAIST discovers pathway to faster-charging, longer-lasting electric vehicle batteries

    29 shares
    Share 12 Tweet 7
  • Blocking glucosylceramide production kills cancer cells via lysosomal dysfunction, not ceramide buildup

    29 shares
    Share 12 Tweet 7
  • ZCCHC4 boosts replication-dependent histone mRNA translation by interacting with eIF3

    29 shares
    Share 12 Tweet 7
  • KAIST Surface Defects Boost Droplet Formation, Removal, and Heat Transfer by 5.5-Fold

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

KAIST discovers pathway to faster-charging, longer-lasting electric vehicle batteries

Blocking glucosylceramide production kills cancer cells via lysosomal dysfunction, not ceramide buildup

ZCCHC4 boosts replication-dependent histone mRNA translation by interacting with eIF3

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 85 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.